Havn Life Sciences Inc. is a biotechnology company focused on the research, development, and commercialization of psychopharmacological products derived from plants and fungi. The company operates at the forefront of psychedelic medicine, aiming to standardize the extraction, formulation, and delivery of psychoactive compounds for use in both clinical research and consumer health applications. Its primary mission is to address mental health challenges such as depression and PTSD by developing innovative therapies and natural healthcare products. Havn Life Sciences collaborates with veterans, researchers, and industry leaders to advance clinical trials related to mental wellness and trauma recovery. With a commitment to evidence-informed research and quality-controlled production, the company aspires to be a leader in setting industry standards for the use of psychedelics in mental health treatment and human performance enhancement. Founded in 2020 and headquartered in Canada, Havn Life Sciences is recognized for pioneering new approaches within the growing psychedelic therapy sector.